Hemoglobin, lactate dehydrogenase, and facit-fatigue normalization rates in patients treated with pegcetacoplan: Results from the pegasus and prince phase 3 clinical trials

被引：0
|
作者：
Mulherin, B. [1 ]
Yeh, M. [2 ,3 ]
Al-Adhami, M. [3 ]
Savage, J. [3 ]
Dingli, D. [4 ]
机构：
[1] Hematol Oncol Indiana, Indianapolis, IN USA
[2] Ascension St Vincent Carmel, Carmel Valley, CA USA
[3] Apellis Pharmaceut, Waltham, MA USA
[4] Mayo Clin, Rochester, MN USA
来源：
BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P272
引用
下载
收藏
页码：246 / 247
页数：2
相关论文
共 50 条
  • [1] Hemoglobin, Lactate Dehydrogenase, and FACIT-Fatigue Normalization in Pegcetacoplan-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria from Two Phase 3 Clinical Trials
    Desai, Dharmik
    Mulherin, Brian P.
    Yeh, Michael
    Al-Adhami, Mohammed
    Savage, Jessica
    Dingli, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S304 - S304
  • [2] Hemoglobin, Lactate Dehydrogenase, and FACIT-Fatigue Normalization in Pegcetacoplan-treated Patients with Paroxysmal Nocturnal Hemoglobinuria
    Tapia, Jose
    Mulherin, Brian
    Yeh, Michael
    Al-Adhami, Mohammed
    Savage, Jessica
    Dingli, David
    ANESTHESIA AND ANALGESIA, 2022, 135 (3S_SUPPL): : 11 - 12
  • [3] Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
    Mulherin, Brian P.
    Yeh, Michael
    Al-Adhami, Mohammed
    Dingli, David
    DRUGS IN R&D, 2024, 24 (02) : 169 - 177
  • [4] Pegcetacoplan Patient Compliance Rates In PEGASUS And PRINCE Phase 3 Trials Compared To Published Oral Medication Compliance Rates In Literature
    Mahajerin, Arash
    Al-Adhami, Mohammed
    Savage, Jessica
    Yeh, Michael
    Dingli, David
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 205 - 206
  • [5] Rapid Time to a Clinically Meaningful Response in FACIT-Fatigue Scores With Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Kaplan-Meier Analysis from the PEGASUS Trial
    Desai, Dharmik
    Fishman, Jesse
    Zhang, Xuan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S306 - S306
  • [6] Pegcetacoplan treatment meaningfully improves quality of life and fatigue in patients with paroxysmal nocturnal hemoglobinuria: results from two phase 3 clinical trials
    Kubal, T.
    Mulherin, B.
    Yeh, M.
    Al-Adhami, M.
    Savage, J.
    Dingli, D.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 468 - 469
  • [7] Derivation via scoring service of PROMIS® fatigue scores based on FACIT-Fatigue Scores from Phase 3 trials with Sarilumab for the Treatment of Rheumatoid Arthritis (RA)
    Bingham, Clifton, III
    Boklage, Susan
    Kimura, Toshio
    Cella, David
    QUALITY OF LIFE RESEARCH, 2019, 28 : S152 - S153
  • [8] Converting FACIT Fatigue to PROMIS Fatigue Scores: Results from Two Phase 3 Baricitinib Rheumatoid Arthritis Trials
    Bartlett, Susan
    Bingham, Clifton
    Cella, David
    DeLozier, Amy
    Quebe, Amanda
    Sun, Luna
    Otawa, Susan
    Gaich, Carol
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 851 - 851
  • [9] Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study
    Wong, Raymond S.
    Navarro, Juan Ramon
    Comia, Narcisa Sonia
    Goh, Yeow Tee
    Idrobo, Henry
    Kongkabpan, Daolada
    Gomez-Almaguer, David
    Al-Adhami, Mohammed
    Ajayi, Temitayo
    Alvarenga, Paulo
    Deschatelets, Pascal
    Francois, Cedric
    Grossi, Federico
    Dumagay, Teresita
    BLOOD, 2021, 138
  • [10] The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from rive randomized clinical trials
    Cella, D
    Kallich, J
    McDermott, A
    Xu, X
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 979 - 986
12345